Literature DB >> 18164561

Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle.

Darwin Sáez1, Ingrid Guzmán, Edilia Andrews, Alex Cabrera, Angel Oñate.   

Abstract

This study was conducted to evaluate the immunogenicity of a DNA or RNA vaccines encoding Brucella abortus Cu-Zn superoxide dismutase (SOD) in cattle. Intramuscular injection of plasmid DNA carrying Brucella SOD gene (pcDNA-SOD) into animals elicited both humoral and cellular immune responses. Animals injected with pcDNA-SOD developed SOD IgG antibody with predominance of immunoglobulin G1 (IgG1) isotype over IgG2. In addition, the DNA vaccine elicited a specific T-cell-proliferative response. Furthermore, intraperitoneal injection of cattle with recombinant Semliki Forest virus particles carrying recombinant RNA encoding SOD (SFV-SOD) did not lead to the induction of SOD IgG 1 or 2 antibody, but induced specific T-cell activation. Both vaccines were able to induce a non-significant secretion of gamma interferon and did not induce the secretion of IL-4 or tumor necrosis factor (TNF)-alpha. These results suggest that SOD gene in a genetic vaccine formulation (DNA or RNA) might be of potential us as a vaccine to induce cell-mediated immunity in cattle. To our knowledge, this is the first study to evaluate a genetic vaccine against Brucella in cattle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164561     DOI: 10.1016/j.vetmic.2007.11.015

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

2.  Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Authors:  Angello Retamal-Díaz; Roberto Riquelme-Neira; Darwin Sáez; Alejandra Rivera; Pablo Fernández; Alex Cabrera; Carlos A Guzmán; Angel Oñate
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

3.  Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Authors:  Nicola J Commander; James M Brewer; Brendan W Wren; Stephen A Spencer; Alastair P Macmillan; Judith A Stack
Journal:  Genet Vaccines Ther       Date:  2010-07-16

4.  Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs.

Authors:  Dina Bugybayeva; Sholpan Ryskeldinova; Nadezhda Zinina; Makhpal Sarmykova; Nurika Assanzhanova; Zhailaubay Kydyrbayev; Kaissar Tabynov
Journal:  Biomed Res Int       Date:  2020-11-19       Impact factor: 3.411

5.  Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies.

Authors:  Sholpan Ryskeldinova; Nadezhda Zinina; Zhailaubay Kydyrbayev; Bolat Yespembetov; Yerken Kozhamkulov; Dulat Inkarbekov; Nurika Assanzhanova; Aigerim Mailybayeva; Dina Bugybayeva; Makhpal Sarmykova; Berik Khairullin; Kairat Tabynov; Aitbay Bulashev; Batyrbek Aitzhanov; Khairulla Abeuov; Abylay Sansyzbay; Tlektes Yespolov; Gourapura J Renukaradhya; Steven Olsen; Angel Oñate; Kaissar Tabynov
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

6.  Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and B. ovis: Comparing Cell-Mediated and Protective Immune Responses Elicited by pCDNA3.1 and pVAX1 DNA Vaccines Coding for Omp31 of Brucella melitensis.

Authors:  Naser Harzandi; Haniyeh Aghababa; Nima Khoramabadi; Termeh Tabaraie
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.